Drug intelligence / Profile preview

ertapenem + meropenem

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous

Overview

Ertapenem + meropenem is a dual carbapenem antibiotic combination therapy used primarily for treating infections caused by carbapenem-resistant organisms. This combination works through a synergistic mechanism where ertapenem acts as a "suicide substrate" that binds to and saturates carbapenemase enzymes, allowing meropenem to reach its target and exert its bactericidal effect. The combination has shown particular efficacy against infections caused by IMP or NDM-producing organisms with lower minimum inhibitory concentrations.

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ertapenem + meropenem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ertapenem + meropenem.

Explore the full profile